Assignee
GEOVAX INC
US·14 granted patents·7 pending applications·16 citations·filing 2012–2023
Top patents by PatentIndex Score
21 records- 0191US11311612B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2018·Granted Apr 26, 2022·6 cites·17 claims
- 0290US11857611B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2022·Granted Jan 2, 2024·2 cites·22 claims
- 0388US11098086B2Multivalent HIV vaccine boost compositions and methods of useGEOVAX INC·Filed 2017·Granted Aug 24, 2021·3 cites·22 claims
- 0485US11278607B2Compositions and methods for generating an immune response to a tumor associated antigenGEOVAX INC·Filed 2017·Granted Mar 22, 2022·2 cites·19 claims
- 0584US11052148B2Compositions and methods for generating an immune response to hepatitis B virusGEOVAX INC·Filed 2017·Granted Jul 6, 2021·2 cites·11 claims
- 0683US12370249B2Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2023·Granted Jul 29, 2025·0 cites·22 claims
- 0782US12329808B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2023·Granted Jun 17, 2025·0 cites·17 claims
- 0881US11413341B2Vaccinia viral vectors encoding chimeric virus like particlesGEOVAX INC·Filed 2020·Granted Aug 16, 2022·1 cites·14 claims
- 0973US12247214B2Vaccinia viral vectors encoding chimeric virus like particlesGEOVAX INC·Filed 2022·Granted Mar 11, 2025·0 cites·21 claims
- 1073US11896657B2Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2022·Granted Feb 13, 2024·0 cites·11 claims
- 1170US11897919B2Multivalent HIV vaccine boost compositions and methods of useGEOVAX INC·Filed 2021·Granted Feb 13, 2024·0 cites·14 claims
- 1270US2023256088A1Immuno-oncology compositions and methods for use thereofGEOVAX INC·Filed 2022·Application pending·0 cites
- 1365US12577589B2Vaccines and uses thereof to induce an immune response to SARS-CoV2GEOVAX INC·Filed 2022·Granted Mar 17, 2026·0 cites·28 claims
- 1464US11638750B2Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 proteinGEOVAX INC·Filed 2020·Granted May 2, 2023·0 cites·22 claims
- 1560US11701418B2Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2016·Granted Jul 18, 2023·0 cites·27 claims
- 1659US2021220469A1Immuno-Oncology Compositions and Methods for Use ThereofGEOVAX INC·Filed 2018·Application pending·0 cites
- 1758US2024344082A1Viral constructs for use in enhancing t-cell priming during vaccinationGEOVAX INC·Filed 2023·Application pending·0 cites
- 1857US2022160853A1Cancer vaccine compositions and methods for use thereofGEOVAX INC·Filed 2021·Application pending·0 cites
- 1951US2019030157A1Compositions and Methods for Generating an Immune Response to a FlavivirusGEOVAX INC·Filed 2017·Application pending·0 cites
- 2046US2020171141A1Compositions and Methods for Generating an Immune Response to LASVGEOVAX INC·Filed 2018·Application pending·0 cites
- 2145US2013280215A1Mva vectors expressing polypeptides and having high level production in certain cell linesGEOVAX INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GEOVAX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →